Built to provide individualized treatments for patients with improved outcomes, Baysient develops SaaS, cloud-based software that provides medical providers with a full line of individual dosage-determination products. Physicians can harness the power of iDose® and T3®, our innovative web-based applications,…
The COVID-19 pandemic has taken a toll on patients and healthcare providers alike, but for patients with inflammatory diseases treated with therapeutic monoclonal antibodies (mAbs), it poses an additional challenge. Baysient's Chief Scientific Officer, Diane Mould, PhD, FCP, FAAPS, recently…
Baysient announces updates to its therapeutic drug monitoring app Time To Target (T3) to enable clinicians to deliver personalized dosing recommendations for the subcutaneous forms of Infliximab and adalimumab. Inflammatory bowel disease (IBD) is a chronic condition affecting approximately 3…
The right dose at the right time is critical for any patient living with a disease. Precision dosing has become a widely discussed topic, and a growing literature recognizes the implications of imprecise dosing on public health, related to both cost…
For patients living with inflammatory bowel disease (IBD), Infliximab (IFX), a monoclonal antibody, has emerged as an efficient treatment for disease activity reduction and IBD patient life quality improvement. However, while IFX is an effective treatment for some patients, a…
Pediatric inflammatory bowel disease (IBD) is a debilitating chronic condition that affects the gastrointestinal tract of children. The symptoms are similar to adults with IBD, but due to the developing immune system, pediatric patients have different needs than adults when…
Blood tests are critical in the medical field for a variety of reasons. Specifically, blood tests can help doctors evaluate how well the organs are working, diagnose diseases, and assess how well your blood is clotting. In addition, a blood…
Baysient’s web-based applications, iDose and T3 were specifically developed to facilitate the dosing of biological agents by integrating real patient’s clinical characteristics. Both softwares use Bayesian models, routine lab results, and demographics to individualize dosing to a specified target trough…
IV Infliximab, a monoclonal antibody, has emerged as an efficient treatment with many clinical benefits, such as quick disease activity reduction and IBD patient life quality improvement. However, drug development of infliximab using weight-based dosing of MAbs without consideration of…
Dr. Marla Dubinsky discusses the unique, personalized, and integrated care offered for children at the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center in a video posted by Mount Sinai Health System. Dr. Dubinsky starts by discussing some…
